Xencor
Licenses Fc-engineered antibody technology to partners while advancing a wholly-owned bispecific pipeline.
$26.05
After-hours close+0.02 (+0.07%)
At close$26.03(−9.87%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.31 | — | — |
| Aug 2026 | −$0.80 | −$0.29 | +63.8% |
| May 2026 | −$0.65 | −$1.71 | −163.1% |
| Feb 2026 | −$0.64 | −$0.09 | +85.9% |
| Nov 2025 | −$0.72 | −$0.08 | +88.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.31 | — | — | $60.4M | — | — |
| Aug 5, 2026 | −$0.80 | −$0.29 | +63.8% | $18.9M | $51.2M | +171.2% |
| May 6, 2026 | −$0.65 | −$1.71 | −163.1% | $27.9M | $4.5M | −83.8% |
| Feb 25, 2026 | −$0.64 | −$0.09 | +85.9% | $30.0M | $28.2M | −5.8% |
| Nov 5, 2025 | −$0.72 | −$0.08 | +88.9% | $30.0M | $21.0M | −29.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 7, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 5, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 8, 2023 | ||||||
| Feb 23, 2023 | ||||||
| Nov 7, 2022 | ||||||
| Aug 3, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 23, 2022 | ||||||
| Nov 8, 2021 | ||||||
| Aug 4, 2021 | ||||||
| May 5, 2021 | ||||||
| Feb 23, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 4, 2020 | ||||||
| May 7, 2020 | ||||||
| Feb 24, 2020 | ||||||
| Nov 5, 2019 | ||||||
| Aug 6, 2019 | ||||||
| May 9, 2019 | ||||||
| Feb 25, 2019 | ||||||
| Nov 5, 2018 | ||||||
| Aug 6, 2018 | ||||||
| May 7, 2018 | ||||||
| Feb 27, 2018 | ||||||
| Nov 7, 2017 | ||||||
| Aug 7, 2017 | ||||||
| May 9, 2017 | ||||||
| Feb 28, 2017 | ||||||
| Nov 2, 2016 | ||||||
| Aug 2, 2016 | ||||||
| May 2, 2016 | ||||||
| Mar 7, 2016 | ||||||
| Nov 3, 2015 | ||||||
| Aug 4, 2015 | ||||||